Find policies, billing codes, payers, states, and providers
Chemotherapy Observation or Inpatient Hospitalization (for New Mexico Only)
Customize your policy alerts
Sign up for UnitedHealthcare Policy CS198NM.C alerts
Get alerted when Policy CS198NM.C changes without checking for updates manually.
Monitor payer policy activity
Medical policy governing when cancer chemotherapy administration requires facility observation or inpatient hospitalization for members in New Mexico (adults only).
Revised drug regimen requirements for an inpatient stay; removed list of applicable cancer type(s) for the listed regimens.
Updated Clinical Evidence and References sections to reflect the most current information.
Archived previous policy version CS198NM.B.
When Observation or Inpatient Care Is Covered
Inpatient medical necessity criteria
Covered as medically necessary inpatient stays when ANY of the following regimen- or condition-based criteria are met:
These regimens are explicitly listed as justifying inpatient stay due to coordination of multiple infusions or monitoring needs.
Policy specifies leucovorin dosing and methotrexate level triggers for escalation of rescue therapy.
Cases outside these listed conditions will be reviewed case‑by‑case (InterQual referenced).
Observation criteria
Covered as observation when ANY of the following conditions are present:
These conditions are identified as indications for observation; other conditions will be reviewed case‑by‑case using InterQual as needed.
This policy applies only to adults. It does not apply to individuals under 18 years of age. Providers should confirm member age when determining whether the policy's observation vs inpatient guidance is applicable.
Per the Policy History effective 08/01/2026, the policy's coverage rationale was updated to revise inpatient regimen requirements and the previous list of applicable cancer type(s) for the listed regimens was removed. This change reflects that the regimens are no longer restricted by specific cancer types in the current policy version.
Regimens Commonly Requiring Inpatient Monitoring
| Regimen | Rationale for inpatient monitoring | Coverage status |
|---|---|---|
| EPOCH / DA‑EPOCH / R‑EPOCH | Multiple continuous infusions over days 1–4 (etoposide and doxorubicin continuous infusion) plus additional agents (cyclophosphamide day 5, with or without rituximab) requiring coordination of multiple drugs/infusions over 96 hours | Covered |
| ESHAP / R‑ESHAP | Multi‑drug regimen with etoposide continuous infusion days 1–4, high‑dose cytarabine and cisplatin continuous infusion days 1–4 — multiple drugs over 96 hours and need to monitor for CNS toxicity from cytarabine | Covered |
| Hyper‑CVAD | Cycles include high‑dose methotrexate and high‑dose cytarabine requiring methotrexate level monitoring and coordination of multiple infusions over 96 hours; bladder irrigation with cyclophosphamide may be required | Covered |
| Regimen / Dose threshold | Monitoring/supportive measures required | Coverage status |
|---|---|---|
| Methotrexate > 500 mg/m2 with leucovorin rescue | Leucovorin 15 mg every 6 hours for eight doses starting 12 hours after infusion; escalate to 50 mg IV q6h for specified methotrexate level thresholds; urine alkalinization and serial methotrexate level monitoring until levels < 0.1 µmol/L | Covered |
| Regimen / Dose | Monitoring/supportive measures required | Coverage status |
|---|---|---|
| Interleukin‑2 600,000 IU/kg IV q8h (up to 14 doses) | Continuous cardiac monitoring; close monitoring of serum electrolytes, creatinine, bilirubin, and urine output; vasopressor support (e.g., dopamine) may be required; proximity to intensive care unit | Covered |
| Regimen / Threshold | Monitoring/supportive measures required | Coverage status |
|---|---|---|
| High‑dose ifosfamide (>1 g/m2/day) | Close monitoring of serum electrolytes and urine pH; electrolyte replacement and urine alkalinization; neurotoxicity monitoring and treatment (e.g., methylene blue) as needed | Covered (often inpatient; outpatient feasible case‑by‑case) |
| Regimen / Setting evaluated | Summary of outpatient feasibility evidence | Coverage status |
|---|---|---|
| High‑dose cytarabine (consolidation) | Small retrospective cohort (Rodrigues et al.) reported outpatient high‑dose cytarabine appeared safe and effective in selected patients, with higher toxicity in patients >50 years; hospitalization required in a portion of outpatient cycles | Informational; requires case‑by‑case review |
| Ambulatory EPOCH regimens | Case series (Keshvani et al.) described ambulatory EPOCH with continuous ambulatory infusion replaced every 24 hours and follow‑up labs twice weekly; small sample with no unexpected safety signals but limited evidence | Informational; requires case‑by‑case review |
Dose Thresholds and Administration Durations That Inform Level of Care
What Providers Must Do / How Requests Are Reviewed
Case-by-case review using InterQual
Cases outside the listed conditions will be reviewed on a case-by-case basis; for medical necessity determinations UnitedHealthcare may assess the level of care using InterQual® Acute Adult Hematology/Oncology criteria (Complications or Disease Progression and/or Treatments).
Prior authorization and plan-specific requirements
Obtain any required prior authorization per the member's plan; UnitedHealthcare may use third-party tools (for example, InterQual®) and plan-specific rules govern coverage decisions.
Provider note — local plan and facility nuances
Follow the policy instructions and organizational expectations for submission and review; preserve this provider-facing note for local plan or facility-specific nuances that may affect authorization or clinical review.
ASCO–ONS responsibilities for antineoplastic therapy
Comply with ASCO–ONS standards: providers share responsibility for ordering, preparing, dispensing, administering, and monitoring antineoplastic therapy as outlined in the 2024 ASCO–ONS guidance.
- Ensure processes for patient consent, education, and monitoring during and after therapy are in place.
Maintain written protocol and follow governing definitions
A written protocol must be followed by the provider administering the chemotherapy drug; refer to federal, state, or contractual definitions that supersede policy definitions when applicable.
- Maintain and make available the written chemotherapy administration protocol on request.
Check federal, state, or contractual plan requirements
Before applying this policy to coverage decisions, check the member’s federal, state, or contractual benefit requirements because those terms govern in case of conflict; this medical policy is informational.
Clinical review required for inpatient stay extensions
Any request to extend an inpatient stay beyond the recommended day(s) requires clinical review; failure to provide clinical justification may risk denial of the extended stay.
Reference governing federal/state/contractual requirements in coverage determinations
Coverage determinations must reference and defer to federal, state, or contractual benefit requirements when they differ from this policy; omissions or failure to reference governing requirements may affect coverage decisions.
Clinical and Operational Background
Chemotherapy may be delivered in the home, physician office, outpatient clinic, or hospital depending on the specific regimen, route of administration, and patient factors. Some regimens or drug doses require inpatient monitoring because they involve multiple drugs or continuous infusions over 96 hours, intensive laboratory or drug-level monitoring (for example, high‑dose methotrexate >500 mg/m2), or therapies that carry elevated risks of acute toxicity. The policy revision clarifies regimen-based inpatient indications and removes prior cancer‑type restrictions while emphasizing that inpatient care is medically necessary when the regimen or patient condition requires coordinated monitoring and supportive care that cannot be provided safely in an outpatient or home setting.
Key Terms and Definitions
Policy Updates and Material Changes
Revised drug regimen requirements for inpatient stay and removed the list of applicable cancer types for the listed regimens; supporting Clinical Evidence and References updated; previous version CS198NM.B archived.
OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.